Table 2.
Groups | N (%) | N of deaths | 5-year survival rate, % | P | Univariate analysis | Multivariate analysis* | ||
---|---|---|---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |||||
Low risk | 117 (62.2) | 30 | 74.6 | 0.006 | 1.00 | 1.00 | ||
Medium risk | 43 (22.9) | 19 | 62.7 | 2.03 (1.14-3.62) | 0.016 | 1.89 (0.99-3.59) | 0.053 | |
High risk | 28 (14.9) | 12 | 57.1 | 2.14 (1.09-4.19) | 0.026 | 2.57 (1.15-5.73) | 0.021 | |
Trend | 1.53 (1.12-2.08) | 0.007 | 1.65 (1.13-2.40) | 0.009 |
Abbreviations: CEA, carcinoembryonic antigen; HR, hazard ratio; CI, confidence interval.
*CEA levels, tumor stage, lymphovascular invasion, perineural invasion, lymph node involvement, and genetic risk classification by miRNA target site SNPs† were included in the multivariate analysis.
†miRNA target site SNPs refer to RPS6KB1 rs1051424 and ZNF839 rs11704.
P < 0.05 are in boldface.